Cargando…

A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8(+) T cell responses

PD-1 and CTLA-4 antibodies offer great hope for cancer immunotherapy. However, many patients are incapable of responding to PD-1 and CTLA-4 blockade and show low response rates due to insufficient immune activation. The combination of checkpoint blockers has been proposed to increase the response ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhai, Wenjie, Zhou, Xiuman, Wang, Hongfei, Li, Wanqiong, Chen, Guanyu, Sui, Xinghua, Li, Guodong, Qi, Yuanming, Gao, Yanfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332792/ https://www.ncbi.nlm.nih.gov/pubmed/32642411 http://dx.doi.org/10.1016/j.apsb.2020.01.005

Ejemplares similares

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progression
por: Chen, Chunxia, et al.
Publicado: (2022)

POTN: A Human Leukocyte Antigen-A2 Immunogenic Peptides Screening Model and Its Applications in Tumor Antigens Prediction
por: Meng, Qingqing, et al.
Publicado: (2020)

Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response
por: Ling, Chen, et al.
Publicado: (2022)

A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy
por: Yan, Zhongyi, et al.
Publicado: (2016)

Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy
por: Niu, Xiaoshuang, et al.
Publicado: (2023)

Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis
por: Gou, Shanshan, et al.
Publicado: (2021)

Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression via AKT/GSK3β/IL-8 signaling pathway
por: Zhao, Yumiao, et al.
Publicado: (2021)

HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response
por: Wu, Yahong, et al.
Publicado: (2018)

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
por: Chen, Shaomeng, et al.
Publicado: (2021)

Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies
por: Chen, Guanyu, et al.
Publicado: (2022)

Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT
por: Zhou, Xiaowen, et al.
Publicado: (2021)

Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
por: Zhou, Xiuman, et al.
Publicado: (2020)

Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma
por: Sui, Xinghua, et al.
Publicado: (2023)

The extracellular death factor (EDF) protects Escherichia coli by scavenging hydroxyl radicals induced by bactericidal antibiotics
por: Yan, Zhongyi, et al.
Publicado: (2015)

Dietary-Polysaccharide-Modified Fish-Oil-Based Double Emulsion as a Functional Colloidal Formulation for Oral Drug Delivery
por: Li, Shuzhen, et al.
Publicado: (2022)

Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy
por: Zhou, Xiuman, et al.
Publicado: (2021)

Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway
por: Sun, Yixuan, et al.
Publicado: (2022)

Identification of CTL Epitopes on Efflux Pumps of the ATP-Binding Cassette and the Major Facilitator Superfamily of Mycobacterium tuberculosis
por: Lin, Yan, et al.
Publicado: (2021)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma
por: Cheung, Chun Chau Lawrence, et al.
Publicado: (2023)

Why is immunotherapy for glioblastoma “Lag”-ging
por: Mathios, Dimitrios, et al.
Publicado: (2019)

LAG3 and its emerging role in cancer immunotherapy
por: Wang, Miao, et al.
Publicado: (2021)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy
por: Michot, Jean-Marie, et al.
Publicado: (2021)

Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells
por: Ma, Jiajia, et al.
Publicado: (2023)

A Novel CTLA-4 affinity peptide for cancer immunotherapy by increasing the integrin αvβ3 targeting
por: Zhou, Ying, et al.
Publicado: (2022)

New emerging targets in cancer immunotherapy: the role of LAG3
por: Puhr, Hannah Christina, et al.
Publicado: (2019)

The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8(+) T cells in the tumor microenvironment
por: Williams, Jason B., et al.
Publicado: (2017)

Identification of HLA-A2-Restricted Mutant Epitopes from Neoantigens of Esophageal Squamous Cell Carcinoma
por: Wang, Zhiwei, et al.
Publicado: (2021)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3
por: Grebinoski, Stephanie, et al.
Publicado: (2022)

Synthesis of bioactive and stabilized cyclic peptides by macrocyclization using C(sp(3))–H activation
por: Tang, Jian, et al.
Publicado: (2017)

Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more
por: Turnis, Meghan E., et al.
Publicado: (2012)

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
por: Long, Long, et al.
Publicado: (2018)

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
por: Ibrahim, Rebecca, et al.
Publicado: (2023)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
por: Gide, Tuba N., et al.
Publicado: (2023)

Control of Tumors by Antigen-Specific CD8(+) T Cells through PDL1-Targeted Delivery of Antigenic Peptide
por: Feng, Po-Hao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2cc7rinbq2g20hg9eqsuuquqhb